

Manfredi Rizzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6964813/publications.pdf>

Version: 2024-02-01

325
papers

12,157
citations

20759

60
h-index

42291

92
g-index

327
all docs

327
docs citations

327
times ranked

13401
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. <i>Fertility and Sterility</i> , 2011, 95, 1073-1079.e11.	0.5	317
2	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
3	Complications of Diabetes 2017. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-4.	1.0	307
4	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , 2017, 75, 307-326.	2.6	294
5	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	2.6	238
6	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	1.2	216
7	Low-density lipoprotein size and cardiovascular risk assessment. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 1-14.	0.2	213
8	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.4	206
9	European Panel on Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. <i>Current Vascular Pharmacology</i> , 2011, 9, 533-571.	0.8	187
10	Association Between Metabolic Syndrome and Periodontitis: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 913-920.	1.8	178
11	An Update on the Role of Markers of Inflammation in Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 1-11.	0.9	169
12	Effects of Coenzyme Q10 on Statin-Induced Myopathy. <i>Mayo Clinic Proceedings</i> , 2015, 90, 24-34.	1.4	168
13	Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 1103-1110.e4.	1.5	161
14	Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. <i>American Journal of Medicine</i> , 2001, 110, 103-110.	0.6	157
15	Analysis of vitamin D levels in patients with and without statin-associated myalgia – A systematic review and meta-analysis of 7 studies with 2420 patients. <i>International Journal of Cardiology</i> , 2015, 178, 111-116.	0.8	154
16	Statin therapy and plasma coenzyme Q10 concentrations – A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	3.1	145
17	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors – Results from a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2015, 189, 47-55.	0.8	138
18	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. <i>Scientific Reports</i> , 2015, 5, 9902.	1.6	133

#	ARTICLE	IF	CITATIONS
19	Management of Statin Intolerance in 2018: Still More Questions Than Answers. American Journal of Cardiovascular Drugs, 2018, 18, 157-173.	1.0	130
20	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care, 2016, 39, 1501-1509.	4.3	126
21	Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. Nutrients, 2013, 5, 928-948.	1.7	124
22	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion on Drug Safety, 2015, 14, 935-955.	1.0	117
23	European Panel On Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. Current Vascular Pharmacology, 2011, 9, 531-532.	0.8	110
24	Atherogenic Lipoprotein Phenotype and Low-Density Lipoproteins Size and Subclasses in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 186-189.	1.8	105
25	Atherogenic dyslipidemia and oxidative stress: a new look. Translational Research, 2009, 153, 217-223.	2.2	105
26	The Role of Fibrate Treatment in Dyslipidemia: An Overview. Current Pharmaceutical Design, 2013, 19, 3124-3131.	0.9	104
27	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2814-2821.	1.8	104
28	Markers of Inflammation and Infection Influence the Outcome of Patients With Baseline Asymptomatic Carotid Lesions. Stroke, 2006, 37, 482-486.	1.0	103
29	Natural approaches in metabolic syndrome management. Archives of Medical Science, 2018, 14, 422-441.	0.4	103
30	Prevalence of dyslipidemia and associated risk factors in Turkish adults. Journal of Clinical Lipidology, 2014, 8, 206-216.	0.6	99
31	Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovascular Diabetology, 2016, 15, 162.	2.7	98
32	Small, dense low-density lipoproteins (LDL) are predictors of cardiovascular events in subjects with the metabolic syndrome. Clinical Endocrinology, 2009, 70, 870-875.	1.2	94
33	Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Frontiers in Pharmacology, 2015, 6, 299.	1.6	92
34	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological Research, 2013, 72, 35-44.	3.1	90
35	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2019, 143, 1-16.	3.1	90
36	COVID-19 and diabetes management: What should be considered?. Diabetes Research and Clinical Practice, 2020, 163, 108151.	1.1	89

#	ARTICLE	IF	CITATIONS
37	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2018, 24, 239-258.	0.9	87
38	Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. <i>Cardiovascular Diabetology</i> , 2014, 13, 49.	2.7	86
39	Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 603-606.	1.8	84
40	Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. <i>Human Reproduction</i> , 2009, 24, 2286-2292.	0.4	80
41	Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 173-175.	0.5	79
42	Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2014, 20, 4961-4969.	0.9	78
43	Should we measure routinely the LDL peak particle size?. <i>International Journal of Cardiology</i> , 2006, 107, 166-170.	0.8	75
44	Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. <i>International Journal of Clinical Practice</i> , 2009, 63, 56-62.	0.8	75
45	Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes. <i>Diabetic Medicine</i> , 2008, 25, 1406-1411.	1.2	74
46	Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1495-1503.	1.9	73
47	Subfractions and Subpopulations of HDL: An Update. <i>Current Medicinal Chemistry</i> , 2014, 21, 2881-2891.	1.2	73
48	Lipid Triad or Atherogenic Lipoprotein Phenotype: A Role in Cardiovascular Prevention?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 237-239.	0.9	70
49	Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study. <i>Coronary Artery Disease</i> , 2008, 19, 139-144.	0.3	69
50	Ethnic differences in serum lipoproteins and their determinants in South African women. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1341-1350.	1.5	69
51	Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. <i>Atherosclerosis</i> , 2008, 197, 237-241.	0.4	66
52	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. <i>International Journal of Cardiology</i> , 2013, 168, 5437-5447.	0.8	66
53	Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. <i>European Heart Journal</i> , 2010, 31, 1633-1639.	1.0	65
54	Small, dense low-density-lipoproteins and the metabolic syndrome. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 14-20.	1.7	64

#	ARTICLE	IF	CITATIONS
55	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 453-461.	2.2	64
56	The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 205-217.	1.3	63
57	Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. <i>Atherosclerosis</i> , 2009, 207, 502-506.	0.4	63
58	Who needs to care about small, dense low-density lipoproteins?. <i>International Journal of Clinical Practice</i> , 2007, 61, 1949-1956.	0.8	62
59	Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 343-349.	0.9	62
60	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 353-368.	2.2	61
61	Hsp60 and heme oxygenase-1 (Hsp32) in acute myocardial infarction. <i>Translational Research</i> , 2011, 157, 285-292.	2.2	60
62	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	3.1	60
63	Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. <i>Advances in Therapy</i> , 2022, 39, 2452-2467.	1.3	58
64	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 576-582.	0.6	56
65	Intensive LDL-cholesterol lowering therapy and neurocognitive function. , 2017, 170, 181-191.		55
66	Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis. <i>Cell Stress and Chaperones</i> , 2014, 19, 343-353.	1.2	54
67	An update on the relationships between rheumatoid arthritis and atherosclerosis. <i>Atherosclerosis</i> , 2010, 212, 377-382.	0.4	52
68	PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3869-3877.	0.9	52
69	NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet. <i>Nutrients</i> , 2017, 9, 492.	1.7	52
70	Long-term consequences of polycystic ovary syndrome on cardiovascular risk. <i>Fertility and Sterility</i> , 2009, 91, 1563-1567.	0.5	51
71	Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 57.	2.0	51
72	Heat-shock protein 60 kDa and atherogenic dyslipidemia in patients with untreated mild periodontitis: a pilot study. <i>Cell Stress and Chaperones</i> , 2012, 17, 399-407.	1.2	49

#	ARTICLE	IF	CITATIONS
73	Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress. <i>Angiology</i> , 2016, 67, 945-950.	0.8	49
74	Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study. <i>Scientific Reports</i> , 2020, 10, 21613.	1.6	47
75	The Clinical Relevance of LDL Size and Subclasses Modulation in Patients with Type-2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 477-482.	0.6	45
76	The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. <i>Lipids in Health and Disease</i> , 2015, 14, 29.	1.2	44
77	Predictors of Insulin Resistance in Patients With Obesity. <i>Angiology</i> , 2014, 65, 22-30.	0.8	42
78	Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?. <i>Atherosclerosis</i> , 2016, 248, 62-75.	0.4	42
79	Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. <i>Diabetes Therapy</i> , 2021, 12, 261-274.	1.2	41
80	Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3858-3868.	0.9	41
81	Low-density-lipoprotein peak particle size in a Mediterranean population. <i>European Journal of Clinical Investigation</i> , 2003, 33, 126-133.	1.7	40
82	Effect of a Natural Supplement Containing <i>Curcuma Longa</i> , Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome. <i>Angiology</i> , 2015, 66, 856-861.	0.8	40
83	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	0.6	40
84	Gemfibrozil Reduces Small Low-Density Lipoprotein More in Normolipemic Subjects Classified as Low-Density Lipoprotein Pattern B Compared With Pattern A. <i>American Journal of Cardiology</i> , 2005, 96, 1266-1272.	0.7	39
85	Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2017, 75, 361-373.	2.6	39
86	Altix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. <i>Nutrients</i> , 2019, 11, 2580.	1.7	39
87	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.	1.6	39
88	An overview of statin-induced myopathy and perspectives for the future. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 601-615.	1.0	38
89	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787761.	1.1	38
90	Effects on Lipoprotein Subclasses of Combined Expression of Human Hepatic Lipase and Human apoB in Transgenic Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 141-146.	1.1	37

#	ARTICLE	IF	CITATIONS
91	Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol. <i>Atherosclerosis</i> , 2008, 200, 389-395.	0.4	37
92	Nutraceuticals in Lipid-Lowering Treatment. <i>Angiology</i> , 2015, 66, 416-421.	0.8	37
93	Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. <i>Phytotherapy Research</i> , 2019, 33, 862-870.	2.8	37
94	Association of Elevated Fibrinogen and C-Reactive Protein Levels with Carotid Lesions in Patients with Newly Diagnosed Hypertension or Type II Diabetes. <i>Archives of Medical Research</i> , 2006, 37, 1004-1009.	1.5	36
95	The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. <i>Current Medical Research and Opinion</i> , 2007, 23, 1103-1111.	0.9	36
96	Heat Shock Protein-60 and Risk for Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 3662-3668.	0.9	36
97	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	0.9	36
98	ETC-1002: A future option for lipid disorders?. <i>Atherosclerosis</i> , 2014, 237, 705-710.	0.4	36
99	Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1391-1397.	1.4	36
100	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154343.	1.5	36
101	The effect of bergamot on dyslipidemia. <i>Phytomedicine</i> , 2016, 23, 1175-1181.	2.3	35
102	Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. <i>Angiology</i> , 2017, 68, 99-108.	0.8	35
103	Small, dense LDL. <i>Current Opinion in Cardiology</i> , 2017, 32, 454-459.	0.8	35
104	Step-by-step diagnosis and management of the nocebo/drug effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	2.9	35
105	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019, 115, 204-212.	1.8	34
106	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. <i>Metabolites</i> , 2020, 10, 392.	1.3	34
107	Long-Term Brain Disorders in Post Covid-19 Neurological Syndrome (PCNS) Patient. <i>Brain Sciences</i> , 2021, 11, 454.	1.1	34
108	Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge. <i>Journal of Clinical Medicine</i> , 2021, 10, 1947.	1.0	34

#	ARTICLE	IF	CITATIONS
109	Overexpression of Human Hepatic Lipase and ApoE in Transgenic Rabbits Attenuates Response to Dietary Cholesterol and Alters Lipoprotein Subclass Distributions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 625-632.	1.1	33
110	Changes in Immunohistochemical Levels and Subcellular Localization After Therapy and Correlation and Colocalization With CD68 Suggest a Pathogenetic Role of Hsp60 in Ulcerative Colitis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 552-561.	0.6	33
111	Effects of Chitosan on Plasma Lipids and Lipoproteins. <i>Angiology</i> , 2014, 65, 538-542.	0.8	33
112	New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension. <i>Angiology</i> , 2014, 65, 333-342.	0.8	33
113	Safety Evaluation of Î±-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. <i>Antioxidants</i> , 2020, 9, 1011.	2.2	33
114	The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. <i>Atherosclerosis</i> , 2009, 204, 330-333.	0.4	32
115	Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. <i>Coronary Artery Disease</i> , 2009, 20, 15-20.	0.3	32
116	Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 647-655.	0.9	32
117	Gender differences in the battle against COVID-19: Impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes. <i>International Journal of Clinical Practice</i> , 2021, 75, e13666.	0.8	32
118	Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 319-325.	0.5	31
119	An evaluation of RVX-208 for the treatment of atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1389-1398.	1.9	31
120	Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review. <i>Medicina (Lithuania)</i> , 2020, 56, 25.	0.8	31
121	Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. <i>Current Pharmaceutical Design</i> , 2017, 23, 2496-2503.	0.9	31
122	Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. <i>Medicina (Lithuania)</i> , 2022, 58, 299.	0.8	31
123	Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. <i>Acta Diabetologica</i> , 2014, 51, 625-632.	1.2	30
124	Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. <i>Diabetes Research and Clinical Practice</i> , 2019, 149, 163-169.	1.1	30
125	Should we routinely measure low-density and high-density lipoprotein subclasses?. <i>Clinical Laboratory</i> , 2009, 55, 421-9.	0.2	30
126	The Relationship between COVID-19 and Hypothalamicâ€Pituitaryâ€Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excessâ€The CAPISCO International Expert Panel. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7326.	1.8	30

#	ARTICLE	IF	CITATIONS
127	New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors. <i>Current Pharmaceutical Design</i> , 2011, 17, 943-949.	0.9	29
128	Serum low density lipoprotein subclasses in Asthma. <i>Respiratory Medicine</i> , 2013, 107, 1866-1872.	1.3	29
129	The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 1187-1197.	4.9	29
130	Future perspectives of the pharmacological management of diabetic dyslipidemia. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 129-143.	1.3	29
131	Exploring the Role of Skeletal Muscle in Insulin Resistance: Lessons from Cultured Cells to Animal Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9327.	1.8	29
132	Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 9-20.	1.0	29
133	Statins and New-Onset Diabetes. <i>Current Pharmaceutical Design</i> , 2014, 20, 3657-3664.	0.9	29
134	Cystatin C levels are decreased in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2005, 101, 213-217.	0.8	28
135	Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 476-484.	1.8	28
136	Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. <i>European Journal of Endocrinology</i> , 2007, 156, 361-367.	1.9	27
137	The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. <i>Acta Diabetologica</i> , 2009, 46, 1-11.	1.2	27
138	LDL size and subclasses in patients with abdominal aortic aneurysm. <i>International Journal of Cardiology</i> , 2009, 134, 406-408.	0.8	27
139	Effects of obesity and estradiol on Na ⁺ /K ⁺ -ATPase and their relevance to cardiovascular diseases. <i>Journal of Endocrinology</i> , 2013, 218, R13-R23.	1.2	27
140	Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation. <i>Current Pharmaceutical Design</i> , 2014, 20, 4953-4960.	0.9	27
141	Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial. <i>Advances in Therapy</i> , 2017, 34, 1966-1975.	1.3	26
142	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options. <i>Biomedicines</i> , 2021, 9, 1579.	1.4	26
143	The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up. <i>Lipids in Health and Disease</i> , 2013, 12, 47.	1.2	25
144	New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby!. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 471-475.	1.5	25

#	ARTICLE	IF	CITATIONS
145	Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 494-496.	1.0	25
146	A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. <i>Metabolites</i> , 2022, 12, 108.	1.3	25
147	Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)]. <i>Current Pharmaceutical Design</i> , 2011, 17, 3608-3610.	0.9	24
148	The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective. <i>Clinical Lipidology</i> , 2013, 8, 173-181.	0.4	24
149	Anti-cytokine therapy for prevention of atherosclerosis. <i>Phytomedicine</i> , 2016, 23, 1198-1210.	2.3	24
150	Association of Simvastatin and Hyperlipidemia With Periodontal Status and Bone Metabolism Markers. <i>Journal of Periodontology</i> , 2014, 85, 1408-1415.	1.7	23
151	Novel Therapeutical Approaches to Managing Atherosclerotic Risk. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4633.	1.8	23
152	Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: The modulation of LDL size and subclasses in high-risk patients. <i>Advances in Therapy</i> , 2007, 24, 575-582.	1.3	22
153	How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 28.e1-28.e5.	0.7	22
154	High-Resolution Computed Tomography Quantitation of Emphysema Is Correlated with Selected Lung Function Values in Stable COPD. <i>Respiration</i> , 2012, 83, 383-390.	1.2	22
155	A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin. <i>Current Pharmaceutical Design</i> , 2013, 19, 4953-4963.	0.9	22
156	The Metabolic Syndrome and HIV Infection. <i>Current Pharmaceutical Design</i> , 2014, 20, 4975-5003.	0.9	22
157	The Role of Endothelium in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11920.	1.8	22
158	The Role of Fructose as a Cardiovascular Risk Factor: An Update. <i>Metabolites</i> , 2022, 12, 67.	1.3	22
159	Fever of unknown origin in a Mediterranean survey from a division of internal medicine: report of 91 cases during a 12-year-period (1991-2002). <i>Internal and Emergency Medicine</i> , 2008, 3, 219-225.	1.0	21
160	Rational for statin use in psoriatic patients. <i>Archives of Dermatological Research</i> , 2013, 305, 467-472.	1.1	21
161	Comparison of Reported Deaths From COVID-19 and Increase in Total Mortality in Italy. <i>JAMA Internal Medicine</i> , 2020, 180, 1250.	2.6	21
162	High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 696-701.	0.6	20

#	ARTICLE	IF	CITATIONS
163	Oxidative stress markers at birth: Analyses of a neonatal population. <i>Acta Histochemica</i> , 2015, 117, 486-491.	0.9	20
164	Plasma heme oxygenase-1 is decreased in peripheral artery disease patients. <i>Molecular Medicine Reports</i> , 2016, 14, 3459-3463.	1.1	20
165	The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 1023-1030.	1.1	20
166	Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 662-668.	1.5	19
167	Low-density lipoprotein size and cardiovascular prevention. <i>European Journal of Internal Medicine</i> , 2006, 17, 77-80.	1.0	19
168	Statins, Fracture Risk, and Bone Remodeling: What Is True?. <i>American Journal of the Medical Sciences</i> , 2006, 332, 55-60.	0.4	19
169	Prediction of Cerebrovascular and Cardiovascular Events in Patients with Subclinical Carotid Atherosclerosis. <i>Journal of Investigative Medicine</i> , 2008, 56, 32-40.	0.7	19
170	Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. <i>Angiology</i> , 2010, 61, 584-590.	0.8	19
171	Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2011, 17, 3699-3712.	0.9	19
172	Postmarketing nutriviigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021, 17, 856-863.	0.4	19
173	Incretin-based therapies in 2021 – Current status and perspectives for the future. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154843.	1.5	19
174	Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives. <i>Current Pharmaceutical Design</i> , 2019, 25, 2038-2050.	0.9	19
175	Vitamin D in the Prevention and Treatment of Diabetic Neuropathy. <i>Clinical Therapeutics</i> , 2022, 44, 813-823.	1.1	19
176	The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2295-2303.	0.9	18
177	The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. <i>Clinica Chimica Acta</i> , 2009, 406, 36-40.	0.5	18
178	Size and Subclasses of Low-Density Lipoproteins in Patients With Obstructive Sleep Apnea. <i>Angiology</i> , 2012, 63, 617-621.	0.8	18
179	Preliminary Results of CitraVesâ, Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study. <i>Metabolites</i> , 2021, 11, 276.	1.3	18
180	The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6627.	1.8	18

#	ARTICLE	IF	CITATIONS
181	LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options. <i>Current Pharmaceutical Design</i> , 2014, 20, 6249-6255.	0.9	18
182	Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002, 89, 460-462.	0.7	17
183	Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. <i>Archives of Medical Science</i> , 2011, 1, 5-7.	0.4	17
184	Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2). <i>Current Pharmaceutical Design</i> , 2011, 17, 3656-3661.	0.9	17
185	Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets. <i>Archives of Medical Science</i> , 2012, 4, 598-600.	0.4	17
186	Pasta Supplemented with <i>Opuntia ficus-indica</i> Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. <i>Metabolites</i> , 2020, 10, 428.	1.3	17
187	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	3.1	17
188	Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action. <i>International Journal of Cardiology</i> , 2021, 329, 205-207.	0.8	17
189	Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 174.	1.0	17
190	Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 483-487.	1.5	16
191	IMPROVE-IT. <i>Current Opinion in Cardiology</i> , 2016, 31, 426-433.	0.8	16
192	NLRP3 Inflammasome Biomarker – Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome. <i>Metabolites</i> , 2020, 10, 448.	1.3	16
193	Hydroxychloroquine, COVID –19 and diabetes. Why it is a different story. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3379.	1.7	16
194	Association between COX-2 rs 6681231 Genotype and Interleukin-6 in Periodontal Connective Tissue. A Pilot Study. <i>PLoS ONE</i> , 2014, 9, e87023.	1.1	16
195	Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2014, 12, 572-585.	0.8	16
196	Metformin: Sex/Gender Differences in Its Uses and Effects – Narrative Review. <i>Medicina (Lithuania)</i> , 2022, 58, 430.	0.8	16
197	Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1308-1316.	1.5	15
198	Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1362-1367.	1.8	15

#	ARTICLE	IF	CITATIONS
199	Recent Insights into the Relationship between Inflammatory Liver Diseases and Atherosclerosis. <i>Journal of Investigative Medicine</i> , 2011, 59, 904-911.	0.7	15
200	Pharmacotherapy for gestational diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1407-1414.	0.9	15
201	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 328-335.	5.4	15
202	The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1309-1315.	1.0	15
203	PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk. <i>Current Pharmaceutical Design</i> , 2017, 23, 894-902.	0.9	15
204	Clinical benefits of ezetimibe use: is absence of proof, proof of absence?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1985-1988.	0.9	14
205	Metabolic disorders during pregnancy and postpartum cardiometabolic risk. <i>Endocrine Connections</i> , 2018, 7, E1-E4.	0.8	14
206	Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108535.	1.1	14
207	Statin intolerance: new data and further options for treatment. <i>Current Opinion in Cardiology</i> , 2021, 36, 487-493.	0.8	14
208	Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166148.	1.8	14
209	Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review. <i>Diabetes Therapy</i> , 2021, 12, 3037-3054.	1.2	14
210	Older age and markers of inflammation are strong predictors of clinical events in women with asymptomatic carotid lesions. <i>Menopause</i> , 2008, 15, 240-247.	0.8	13
211	Metabolic Syndrome and Vitamin D Levels in Patients with Obstructive Sleep Apnea Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 190-196.	0.5	13
212	Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. <i>Acta Diabetologica</i> , 2019, 56, 289-299.	1.2	13
213	Incretins, Pregnancy, and Gestational Diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 597-602.	0.9	13
214	Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12409.	1.8	13
215	Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study. <i>Diabetes Therapy</i> , 2022, 13, 453-464.	1.2	13
216	Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. <i>European Journal of Clinical Investigation</i> , 2013, 43, 698-707.	1.7	12

#	ARTICLE	IF	CITATIONS
217	Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 1-10.	0.5	12
218	Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10038.	1.8	12
219	A New Comorbidity in Periodontitis: <i>Fusobacterium nucleatum</i> and Colorectal Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 546.	0.8	12
220	Hypothyroidism and Risk of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2022, 28, 2065-2072.	0.9	12
221	Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions. <i>Metabolites</i> , 2022, 12, 639.	1.3	12
222	Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 361-367.	1.1	11
223	Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 38-46.	0.9	11
224	Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 902.	1.8	11
225	A case of bowel schistosomiasis not adhering to endoscopic findings. <i>World Journal of Gastroenterology</i> , 2005, 11, 7044.	1.4	11
226	Editorial The effects of statins on blood pressure: current knowledge and future perspectives. <i>Archives of Medical Science</i> , 2012, 1, 1-3.	0.4	10
227	Non-glycemic effects of pioglitazone and incretin-based therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 739-742.	1.5	10
228	Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial. <i>PLoS ONE</i> , 2014, 9, e91565.	1.1	10
229	Managing the Systemic Impact of Periodontitis. <i>Medicina (Lithuania)</i> , 2022, 58, 621.	0.8	10
230	Nonalcoholic Fatty Liver Disease, Cardiovascular Risk, and Carotid Inflammation. <i>Angiology</i> , 2015, 66, 601-603.	0.8	9
231	Atorvastatin treatment increases plasma bilirubin but not <i>HMOX1</i> expression in stable angina patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 382-389.	0.6	9
232	Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect. <i>Metabolites</i> , 2020, 10, 391.	1.3	9
233	Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2021, 27, 3729-3740.	0.9	9
234	Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108935.	1.1	9

#	ARTICLE	IF	CITATIONS
235	Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers. <i>Current Pharmaceutical Design</i> , 2019, 25, 3704-3714.	0.9	9
236	Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). <i>Diabetes Therapy</i> , 2022, 13, 795-810.	1.2	9
237	Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk. <i>Clinical Endocrinology</i> , 2012, 76, 177-178.	1.2	8
238	Editorial Statin treatment in the elderly: how much do we know?. <i>Archives of Medical Science</i> , 2013, 4, 585-588.	0.4	8
239	A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin. <i>Oncotarget</i> , 2019, 10, 1284-1305.	0.8	8
240	CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. <i>Metabolites</i> , 2021, 11, 857.	1.3	8
241	Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: Pleiotropic evidence from plasma mRNA analyses. <i>Clinical Biochemistry</i> , 2013, 46, 1526-1531.	0.8	7
242	Novel anti-obesity drugs and plasma lipids. <i>Clinical Lipidology</i> , 2014, 9, 179-187.	0.4	7
243	The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review. <i>Lipids in Health and Disease</i> , 2017, 16, 35.	1.2	7
244	Metabolic Syndrome in Patients with Coexistent Obstructive Sleep Apnea Syndrome and Chronic Obstructive Pulmonary Disease (Overlap Syndrome). <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 296-301.	0.5	7
245	Efficacy of a fasting-mimicking diet in functional therapy for depression: A randomised controlled pilot trial. <i>Journal of Clinical Psychology</i> , 2020, 76, 1807-1817.	1.0	7
246	New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?. <i>Diabetes Therapy</i> , 2021, 12, 1605-1611.	1.2	7
247	Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9378.	1.8	7
248	Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12311.	1.8	7
249	Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency. <i>Growth Hormone and IGF Research</i> , 2008, 18, 264-266.	0.5	6
250	Emerging approaches for the treatment of hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1869-1873.	0.9	6
251	Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH. <i>Current Vascular Pharmacology</i> , 2014, 12, 741-744.	0.8	6
252	Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 281-284.	0.9	6

#	ARTICLE	IF	CITATIONS
253	PPAR in Cardiovascular Disorders. PPAR Research, 2016, 2016, 1-2.	1.1	6
254	In vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters. Atherosclerosis, 2016, 251, 147-152.	0.4	6
255	Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review). Experimental and Therapeutic Medicine, 2020, 21, 90.	0.8	6
256	Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opinion on Drug Safety, 2022, 21, 291-293.	1.0	6
257	Is diabetes the cost to pay for a greater cardiovascular prevention?. International Journal of Cardiology, 2010, 144, 309-310.	0.8	5
258	Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 613-614.	2.2	5
259	Statins in liver disease: not only prevention of cardiovascular events. Expert Review of Gastroenterology and Hepatology, 2018, 12, 743-744.	1.4	5
260	Diabetes and COVID-19: A Tale of 2 Pandemics. Journal of Cardiovascular Pharmacology, 2021, 78, e1-e2.	0.8	5
261	Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective. Metabolites, 2021, 11, 611.	1.3	5
262	Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs: the Investigational Drugs Journal, 2010, 13, 103-11.	0.7	5
263	Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. Pharmaceutics, 2022, 14, 825.	2.0	5
264	Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. Metabolic Syndrome and Related Disorders, 2021, , .	0.5	5
265	Therapy with noninvasive ventilation in patients with obstructive sleep apnoea: Effects on atherogenic lipoprotein phenotype. Medical Hypotheses, 2009, 73, 441-444.	0.8	4
266	Oxidative stress and small, dense low-density lipoproteins: current and future perspectives. Expert Review of Endocrinology and Metabolism, 2012, 7, 415-417.	1.2	4
267	Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea. Angiology, 2016, 67, 937-944.	0.8	4
268	GLP-1 receptor agonists, carotid atherosclerosis and retinopathy. Expert Opinion on Pharmacotherapy, 2017, 18, 1163-1165.	0.9	4
269	New antihyperglycaemic agents and cardiovascular disease. Current Opinion in Cardiology, 2018, 33, 444-454.	0.8	4
270	Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease. Metabolites, 2021, 11, 425.	1.3	4

#	ARTICLE	IF	CITATIONS
271	Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care. <i>Medicina (Lithuania)</i> , 2021, 57, 805.	0.8	4
272	Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2022, 34, S24-S31.	0.4	4
273	The Endometrial Transcriptome of Metabolic and Inflammatory Pathways During the Window of Implantation Is Deranged in Infertile Obese Polycystic Ovarian Syndrome Women. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 384-394.	0.5	4
274	Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. <i>Clinica Chimica Acta</i> , 2003, 328, 91-97.	0.5	3
275	The Role of Elevated Growth Hormone on the Increased Atherosclerosis in Patients With Acromegaly. <i>Angiology</i> , 2012, 63, 492-494.	0.8	3
276	Serum lipoproteins are not associated with the severity of asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 57-61.	1.1	3
277	Microvascular and macrovascular effects of liraglutide. <i>International Journal of Cardiology</i> , 2019, 286, 17-18.	0.8	3
278	Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion. <i>European Journal of Integrative Medicine</i> , 2020, 37, 101164.	0.8	3
279	Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?. <i>Annals of Translational Medicine</i> , 2018, 6, S79-S79.	0.7	3
280	Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a cellular metabolic treatment legacy effect?. <i>Endocrine</i> , 2021, , 1.	1.1	3
281	Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. <i>Medicina (Lithuania)</i> , 2022, 58, 109.	0.8	3
282	The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update. <i>Metabolites</i> , 2022, 12, 131.	1.3	3
283	Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema – A Systematic Review. <i>Current Pharmaceutical Design</i> , 2022, 28, 1758-1768.	0.9	3
284	Obesity and HFpEF. <i>Journal of Clinical Medicine</i> , 2022, 11, 3858.	1.0	3
285	The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis. <i>Vascular Disease Prevention</i> , 2006, 3, 269-274.	0.2	2
286	Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?. <i>Clinical Lipidology</i> , 2013, 8, 273-277.	0.4	2
287	Treatment options for managing atherogenic dyslipidemia and fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1065-1068.	0.9	2
288	Periodontitis, blood lipids and lipoproteins. <i>Clinical Lipidology</i> , 2014, 9, 261-276.	0.4	2

#	ARTICLE	IF	CITATIONS
289	A Potential Link between Serum Low-Density Lipoproteins and Asthma. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 261-262.	2.5	2
290	Can the effects of gender, menopause and ageing on lipid levels be differentiated?. Clinical Endocrinology, 2016, 85, 694-695.	1.2	2
291	Psoriasis and acute coronary syndrome risk. International Journal of Cardiology, 2019, 286, 15-16.	0.8	2
292	Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children. Expert Opinion on Pharmacotherapy, 2019, 20, 241-244.	0.9	2
293	Effect of Statins on Low-density lipoprotein Size: A New Role in Cardiovascular Prevention?. Southern Medical Journal, 2006, 99, 1015-1016.	0.3	2
294	Update on the role of the atherogenic lipoprotein phenotype in cardiovascular prevention. Future Cardiology, 2007, 3, 553-558.	0.5	1
295	Editorial [Inflammation and Atherosclerosis: Recent Insights and Future Perspectives]. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2008, 7, 150-151.	1.1	1
296	Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. Clinical Lipidology, 2011, 6, 539-547.	0.4	1
297	The Role of Macrophage Colony-Stimulating Factor in Patients With Acute Myocardial Infarction. Angiology, 2012, 63, 127-130.	0.8	1
298	Mipomersen: a lipid-lowering agent with a novel mechanism of action. Clinical Lipidology, 2013, 8, 279-282.	0.4	1
299	Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic Tj ETQq1 1 0.784314 ggBT /Overlock 10 Tf	0.9	1
300	High-Sensitivity C-Reactive Protein and Statin Initiation. Angiology, 2015, 66, 503-507.	0.8	1
301	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1
302	Advances in pharmacological treatment of type 1 diabetes during pregnancy. Expert Opinion on Pharmacotherapy, 2019, 20, 983-989.	0.9	1
303	The Consumption of Fast Food Favors Weight Increase in Young Hellenic Navy Personnel: A 10-Year Follow-Up Study. Metabolic Syndrome and Related Disorders, 2020, 18, 493-497.	0.5	1
304	Metabolic effect of berberine+silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. , 2019, 33, 862.		1
305	Nutraceuticals and Lipid Management. Contemporary Cardiology, 2021, , 173-189.	0.0	1
306	Treating Arterial Stiffness Associated with Features of Metabolic Syndrome Not Included in its Diagnostic Criteria: Cutting Off the Heads of Lernaean Hydra, Keeper of the Underworld. Open Hypertension Journal, 2013, 5, 67-74.	0.8	1

#	ARTICLE	IF	CITATIONS
307	When Periods Stop: Long-Term Consequences of PCOS. , 2009, , 265-270.		1
308	Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice. Advances in Therapy, 2021, , 1.	1.3	1
309	Molecular Endocrinology and Metabolism in 2021: What's New. International Journal of Molecular Sciences, 2021, 22, 13375.	1.8	1
310	Treatment of diabetes and heart failure: Facts and hopes. International Journal of Cardiology, 2022, , .	0.8	1
311	Non-alcoholic Fatty Liver Disease, Metabolic syndrome, and Type 2 diabetes mellitus: Where do we stand today?. Archives of Medical Science, 0, , .	0.4	1
312	Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Review of Cardiovascular Therapy, 0, , 1-13.	0.6	1
313	Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. European Journal of Endocrinology, 2004, 150, 831-836.	1.9	0
314	Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. European Journal of Endocrinology, 2008, 159, 355.	1.9	0
315	Recent Insights on Dark Chocolate Consumption and Cardiovascular Risk. Southern Medical Journal, 2008, 101, 1194.	0.3	0
316	Smoking and Small, Dense Low-Density Lipoproteins. Angiology, 2013, 64, 563-563.	0.8	0
317	Postprandial metabolism: from research to clinical practice. Clinical Lipidology, 2013, 8, 395-398.	0.4	0
318	Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!. Current Medical Research and Opinion, 2014, 30, 2425-2428.	0.9	0
319	The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam?. Cardiovascular Drugs and Therapy, 2014, 28, 205-207.	1.3	0
320	Nutraceuticals and Cardiovascular Disease. Contemporary Cardiology, 2021, , 67-87.	0.0	0
321	Future Perspectives in Nutraceutical Research. Contemporary Cardiology, 2021, , 289-293.	0.0	0
322	Cardiovascular and Cardioprotective Agents in 2021. Current Pharmaceutical Design, 2021, 27, 2915-2916.	0.9	0
323	Do We Need Better Lipid Tools for Cardiovascular Risk Assessment?. Southern Medical Journal, 2008, 101, 221.	0.3	0
324	The Clinical Significance of Small, Dense Low-Density Lipoproteins. , 2006, , 168-185.		0

#	ARTICLE	IF	CITATIONS
325	Effects of Armolipid Plus® on small dense LDL particles. <i>Clinical Lipidology</i> , 2016, 11, 39-40.	0.4	0